1. [Mifepristone: from pre- to post-protection].
- Author
-
Kleiverda G, Dehue GCG, and Gomperts RJ
- Subjects
- Female, Humans, Contraceptives, Oral, Hormonal adverse effects, Estrogens, Netherlands, Mifepristone, Progestins
- Abstract
All current hormonal contraceptives have side effects and contraindications related to estrogens and progestins. Users are often dissatisfied with this. There is a great need for a new contraceptive drug without these hormones with the associated side effects and contraindications; with also a favorable bleeding profile; that can be used orally and not daily; that can serve as a contraceptive and after-care and can also be used on demand. Mifepristone 50 mg seems to provide the answer to all these wishes but is not (yet) registered in the Netherlands.
- Published
- 2022